CE Activities

Defining Disease Response and Progression: Treatment Resistance, Failure and/or Loss of Response
Defining Disease Response and Progression: Treatment Resistance, Failure and/or Loss of Response
CME, NCPD, CPE
Prithviraj Bose, MD; and John Mascarenhas, MD
Release Date: November 11, 2022
Expiration Date: November 11, 2023

Several JAK inhibitors are now approved for the treatment of myelofibrosis (MF). Ruxolitinib is considered the standard of care for managing symptomatic MF and, as such, is most often used in the frontline treatment setting. Peer-reviewed literature reflects the pervasive use of ruxolitinib in the frontline MF setting, and the overwhelming majority of data available for study and review in these patients involves ruxolitinib. This data is clear: the majority of patients will either fail to respond or lose response to ruxolitinib over time. Treatment resistance and loss of response can be difficult to identify and define. In this activity, two experts describe risk factors for disease progression, review methods of assessing for and identifying resistance, and how to manage treatment failure.

Provided by The University of Texas MD Anderson Cancer Center and MediCom Worldwide, Inc.
This activity is supported by educational grants from Bristol Myers Squibb, CTI BioPharma Corp. and Sierra Oncology.
Begin, Earn CreditView Only, No Credit
 
Risk-adapted Therapy for PV
Risk-adapted Therapy for PV
CME, CPE
Jerry L. Spivak, MD, MACP
Release Date: October 18, 2021
Expiration Date: October 18, 2022

Join Dr. Spivak as he discusses risk stratification and management strategies for polycythemia vera (PV). Topics include the pathophysiology and mutational foundation of PV, predicting risk and PV prognosis, current treatment strategies and controversies, and the role of targeted therapies in managing PV.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Bristol-Myers Squibb and Incyte Corporation.
CE ExpiredView Only, No Credit
 
Novel Agents and Treatment Strategies for Relapsed/Refractory MF
Novel Agents and Treatment Strategies for Relapsed/Refractory MF
CME, CPE
John Mascarenhas, MD
Release Date: July 14, 2021
Expiration Date: July 14, 2022

Join Dr. Mascarenhas as he discusses new and emerging treatment approaches for relapsed/refractory myelofibrosis (MF). Topics include a review of the COMFORT-1 and -2 and the JAKARTA2 trials of ruxolitinib and fedratinib, and recently released outcomes of trials evaluating investigational agents such as momelotinib, pacritinib, navitoclax, pelabresib, and imetelstat.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Bristol-Myers Squibb and Incyte Corporation.
CE ExpiredView Only, No Credit
 
The Expanding Role of JAK Inhibitors in MF
The Expanding Role of JAK Inhibitors in MF
CME, CPE
Ruben Mesa, MD
Release Date: June 16, 2021
Expiration Date: June 16, 2022

Join Dr. Mesa as he discusses new opportunities for JAK inhibitors in myelofibrosis (MF). Topics will include the ruxolitinib phase 3 COMFORT I and II trials, management of early-onset treatment-associated cytopenia, and outcomes associated with fedratinib in the JAKARTA and JAKARTA-2 trials

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Bristol-Myers Squibb and Incyte Corporation.
CE ExpiredView Only, No Credit
 
Treatment of MF-associated Anemia
Treatment of MF-associated Anemia
CME, CPE
Srdan Verstovsek, MD, PhD
Release Date: April 23, 2021
Expiration Date: April 23, 2022

In this activity, Dr. Srdan Verstovsek will discuss management of myelofibrosis-associated anemia. He will provide guidance on thresholds for red blood cell transfusion, criteria for selecting anemia therapy, and current and emerging treatment options for managing anemia, including erythropoiesis-stimulating agents (ESAs), anabolic steroids, corticosteroids, immunomodulatory agents, Janus kinase (JAK) inhibitors, anti-hemojuvelin antibodies, ALK2 receptor inhibitors, and luspatercept.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Bristol-Myers Squibb and Incyte Corporation.
CE ExpiredView Only, No Credit
 
ASH 2020 Meeting Highlights in Myeloproliferative Neoplasms
ASH 2020 Meeting Highlights in Myeloproliferative Neoplasms
CME, CPE, CNE
Ruben Mesa, MD; Aaron T. Gerds, MD; and John Mascarenhas, MD
Release Date: April 05, 2021
Expiration Date: April 05, 2022

Explore new data on MPN presented at the 2020 ASH Annual meeting. In this activity, experts will discuss long-term outcomes of the CONTINUATION-PV trial comparing ropegylated interferon versus hydroxyurea; phase 2 study results of idasanutlin as second-line therapy; the efficacy of PTG-300 for anemia; results from the SIMPLIFY-2 study of momelotinib; data on CPI-0610; outcomes of imetelstat in high-risk patients; navitoclax in relapsed/refractory myelofibrosis; and the potential utility of the LSD1 inhibitor bomedemstat (IMG-7289).

This activity was previously presented as a live webinar with Q&A on March 08, 2021. Please note: If you participated in the live webinar, you are ineligible to receive an additional 1.0 contact hour of credit and may not re-submit for credit previously awarded.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Bristol-Myers Squibb and Incyte Corporation.
CE ExpiredView Only, No Credit
 
MPN Driver Genes and the Importance of Molecular Genetic Testing
MPN Driver Genes and the Importance of Molecular Genetic Testing
CME, CPE
Aaron T. Gerds, MD
Release Date: February 17, 2021
Expiration Date: February 17, 2022

Mutational testing is an integral part of the management of myeloproliferative neoplasms (MPNs), as results from this assessment can both guide treatment selection and provide prognostic information. In this article, Dr. Aaron Gerds discusses best practice regarding the utility of mutational testing in clinical practice when treating patients with MPNs.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Bristol-Myers Squibb and Incyte Corporation.
CE ExpiredView Only, No Credit
 
Emerging Therapies in PV
Emerging Therapies in PV
CME, CPE
Raajit K. Rampal, MD, PhD
Release Date: December 21, 2020
Expiration Date: December 21, 2021

Approaching management and diagnosis of a patient with polycythemia vera (PV) can be challenging. In this activity, Dr. Rampal explains the goals of therapy, prognostication of thrombosis, and therapies in first-line treatment. He also discusses the patient-related features to consider when developing a treatment plan.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Bristol-Myers Squibb and Incyte Corporation.
CE ExpiredView Only, No Credit
 
Myeloproliferative Neoplasms: Integrating New Therapies Into Challenging Case Scenarios
Myeloproliferative Neoplasms: Integrating New Therapies Into Challenging Case Scenarios
CME, CPE, CNE
Prithviraj Bose, MD – Chair; Ruben Mesa, MD; Raajit K. Rampal, MD, PhD
Release Date: September 14, 2020
Expiration Date: September 14, 2021

Management of myeloproliferative neoplasms has evolved considerably since the identification of JAK2 and targeted therapy that has improved disease-related symptoms and quality of life. Our renowned faculty will provide updates in the latest data related to diagnosis, treatment options, guidelines, and standards of care through a highly interactive educational experience. Three real-life case scenarios will be presented, and the faculty will discuss treatment options and the journey of each patient.

This activity was previously presented as a webinar with live Q&A in September of 2020. Please note: If you participated in the live webinar, you are ineligible to receive an additional 1.25 contact hours of credit and may not re-submit for credit previously awarded.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Bristol-Myers Squibb and Incyte Corporation.
CE ExpiredView Only, No Credit
 
Future Directions in Myelofibrosis Therapy: Emerging Novel Agents and New Treatment Strategies
Future Directions in Myelofibrosis Therapy: Emerging Novel Agents and New Treatment Strategies
CME, CPE
Elizabeth Hexner, MD
Release Date: July 13, 2020
Expiration Date: July 13, 2021

The approval of ruxolitinib established JAK inhibitor therapy as the standard of care for intermediate- and high-risk myelofibrosis (MF), and the recent approval of fedratinib further supports the important role of JAK inhibitors in this setting. There is an urgent need for novel targeted therapies and new approaches. This article summarizes some of the most compelling data from key clinical trials investigating novel treatment approaches for MF and concludes with strategies to improve physician-patient communication.

Provided by MediCom Worldwide, Inc.
This activity is supported by an educational grant from Incyte Corporation
CE ExpiredView Only, No Credit
 
Current Treatment of Myelofibrosis: Old Standards and New Options
Current Treatment of Myelofibrosis: Old Standards and New Options
CME, CPE
Elizabeth Hexner, MD
Release Date: June 29, 2020
Expiration Date: June 29, 2021

It is well known that JAK/STAT signaling plays a central role in the pathogenesis of myelofibrosis (MF), and the demonstrated efficacy of the JAK inhibitor ruxolitinib in myelofibrosis has established it as standard of care in intermediate- and high-risk disease. Based on the success of ruxolitinib in this setting, other JAK inhibitors have been under investigation to further improve clinical outcomes in MF. The recent approval of fedratinib in both the frontline and second-line setting has expanded treatment options for MF, and pacritinib and momelotinib are also showing great promise in clinical trials. In this article, Dr. Elizabeth Hexner will review recent data supporting the role of JAK inhibitors for the treatment of MF.

Provided by MediCom Worldwide, Inc.
This activity is supported by an educational grant from Incyte Corporation
CE ExpiredView Only, No Credit